EPISODE · Oct 22, 2025 · 20 MIN
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
from WTR Healthcare Happenings
In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.
What this episode covers
In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation ...
NOW PLAYING
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
No transcript for this episode yet
Similar Episodes
No similar episodes found.